



**HAL**  
open science

## Nitrone-Trolox conjugate as an inhibitor of lipid oxidation: Towards synergistic antioxidant effects

Larissa Socrier, Marie Rosselin, Ana Milena Gomez Giraldo, Benjamin Chantemargue, Florent Di Meo, Patrick Trouillas, Grégory Durand, Sandrine Morandat

### ► To cite this version:

Larissa Socrier, Marie Rosselin, Ana Milena Gomez Giraldo, Benjamin Chantemargue, Florent Di Meo, et al.. Nitrone-Trolox conjugate as an inhibitor of lipid oxidation: Towards synergistic antioxidant effects. *Biochimica et Biophysica Acta:Biomembranes*, 2019, 1861, pp.1489 - 1501. 10.1016/j.bbamem.2019.06.008 . hal-03488134

**HAL Id: hal-03488134**

**<https://hal.science/hal-03488134>**

Submitted on 20 Dec 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

1 **Nitrone-Trolox conjugate as an inhibitor of lipid oxidation: Towards synergistic antioxidant effects**

2 Larissa Socrier<sup>a,\*</sup>, Marie Rosselin<sup>b</sup>, Ana Milena Gomez Giraldo<sup>a</sup>, Benjamin Chantemargue<sup>c, d</sup>, Florent Di

3 Meo<sup>c</sup>, Patrick Trouillas<sup>c, d</sup>, Grégory Durand<sup>b</sup> and Sandrine Morandat<sup>a</sup>

4

5 <sup>a</sup>Sorbonne Universités, Université de technologie de Compiègne. CNRS, Génie Enzymatique et Cellulaire, FRE

6 3580. Centre de recherches Royallieu, CS 60319 – 60203 Compiègne cedex, France;

7 <sup>b</sup>Institut des Biomolécules Max Mousseron (UMR 5247 CNRS-Université Montpellier-ENSCM) & Avignon

8 University, Equipe Chimie Bioorganique et Systèmes Amphiphiles, 301 rue Baruch de Spinoza, F-84916 Avignon

9 Cedex 9, France ;

10 <sup>c</sup>INSERM, Univ. Limoges, IPPRITT, U1248, Faculty of Pharmacy, 2 rue du Dr Marcland, 87025 Limoges, France;

11 <sup>d</sup>RCPTM, Palacký University, Faculty of Sciences, Šlechtitelů 27, 78371, Olomouc, Czech Republic

12

13 \*Corresponding author: las218@lehigh.edu, Tel: +1 (610) 758 5328

14 Present address: Lehigh University, Department of Physics. 416 Lewis Laboratory, 16 Memorial Drive East. Bethlehem,

15 Pennsylvania, 18 015. USA.

16

17 **Abstract**

18 Free radical scavengers like  $\alpha$ -phenyl-*N*-*tert*-butylnitron (PBN) and 6-hydroxy-2,5,7,8-  
19 tetramethylchroman-2-carboxylic acid (Trolox) have been widely used as protective agents in various  
20 biomimetic and biological models. A series of three amphiphilic Trolox and PBN derivatives have been  
21 designed by adding to those molecules a perfluorinated chain as well as a sugar group in order to  
22 render them amphiphilic. In this work, we have studied the interactions between these derivatives and  
23 lipid membranes to understand how they influence their ability to prevent membrane lipid oxidation.  
24 We showed the derivatives better inhibited the AAPH-induced oxidation of 1,2-dilinoleoyl-*sn*-glycero-  
25 3-phosphocholine (DLiPC) small unilamellar vesicles (SUVs) than the parent compounds. One of the  
26 derivatives, bearing both PBN and Trolox moieties on the same fluorinated carrier, exhibited a  
27 synergistic antioxidant effect by delaying the oxidation process. We next investigated the ability of the  
28 derivatives to interact with DLiPC membranes in order to better understand the differences observed  
29 regarding the antioxidant properties. Surface tension and fluorescence spectroscopy experiments  
30 revealed the derivatives exhibited the ability to form monolayers at the air/water interface and  
31 spontaneously penetrated lipid membranes, underlying pronounced hydrophobic properties in  
32 comparison to the parent compounds. We observed a correlation between the hydrophobic  
33 properties, the depth of penetration and the antioxidant properties and showed that the location of  
34 these derivatives in the membrane is a key parameter to rationalize their antioxidant efficiency.  
35 Molecular dynamics (MD) simulations supported the understanding of the mechanism of action,  
36 highlighting various key physical-chemical descriptors.

37

38 **Key words:** model membranes; lipid oxidation; amphiphilic nitron; Trolox; antioxidant; synergism

## 39 1. Introduction

40 Reactive oxygen species (ROS) are produced in living organisms and are involved in several  
41 important biological processes such as signaling pathways [1], antimicrobial defense [2] or cell  
42 adhesion [3]. However, the deregulation of physiological processes as well as the exposure to  
43 environmental factors like pollution, radiations or tobacco smoke may favor an overproduction of ROS  
44 [4], which unbalance the redox status of cells and lead to oxidative stress. Because of their ability to  
45 damage biomolecules, in particular membrane polyunsaturated lipids which are degraded through a  
46 reaction named lipid peroxidation [5]; ROS are involved in the early stages of various diseases [6–8] as  
47 well as the deterioration of cosmetic [9], food [10,11] and pharmaceutical supplies [12].

48 In order to limit the deleterious effects of ROS, living organisms use several antioxidant defense  
49 systems that are either endogenous – mainly enzymes but also small molecules such as glutathione –  
50 or exogenous [13]. Exogenous antioxidants, essentially polyphenols and vitamins, come from food. To  
51 improve their properties, bioinspired molecules have been developed based on these natural  
52 compounds. In this regard, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid), a water  
53 soluble analog of  $\alpha$ -tocopherol, has been used to prevent apoptosis [14], *in vitro* or *ex vivo* ischemia  
54 [15] and membrane lipid oxidation [16]. Trolox is also used as a reference in the evaluation of  
55 antioxidant activities. Namely, the Trolox equivalent antioxidant capacity (TEAC) parameter measures  
56 the potency of a given antioxidant. TEAC also allows the comparison of antioxidant efficiency of food  
57 matrices and beverages, for which isolation of molecules can rarely be achieved [17,18]. Also,  
58 because of their enhanced reactivity against free radicals, spin trapping agents can be used as free  
59 radical scavengers [19]. Among them,  $\alpha$ -phenyl-*N*-*tert*-butylnitron (PBN) is one of the most popular.  
60 PBN was initially used in electron spin resonance (ESR) experiments for the detection of free radicals  
61 under chemical and biological environments, however, it has later been used in biological models as an  
62 antioxidant [20,21]. Although PBN has the advantage of being a non-toxic chemically stable antioxidant  
63 with a half-life of six hours in animals [22], it presents like Trolox a poor ability to remain inside

64 membranes. To create antioxidants with a greater hydrophobicity and therefore a better affinity for  
65 membranes, several molecules deriving from PBN and Trolox have been designed. For instance, Ayuso  
66 *et al.* [23], as well as Choteau *et al.* [24], reported the synthesis of PBN derivatives bearing a  
67 cholesterol moiety. In both cases, these authors demonstrated that compared to PBN, the derivatives  
68 presented an enhanced protective activity against stroke and retina light-induced damages,  
69 respectively. Besides the need of increasing the affinity for the membrane, a strategy that has gained  
70 attention is to combine two (or more) antioxidant moieties in a single molecule [25]. In this regard,  
71 Trolox was combined to lipoic acid [26], silybin [27] as well as a nitric oxide synthase inhibitor [28].  
72 Along the same line, Trolox and PBN amphiphilic derivatives [29,30] have recently been synthesized.  
73 They bear, on one hand, a perfluorinated chain to increase hydrophobicity without inducing a cytolytic  
74 effect [31] and on the other hand, a sugar group to maintain water solubility (Fig. 1).

75 In the present work, we have studied the antioxidant properties of these derivatives related to  
76 their capacity to interact with lipid membranes, which in turn has allowed unraveling their antioxidant  
77 properties by using biomimetic systems. The antioxidant action at the membrane was evaluated by  
78 performing Langmuir monolayers and lipid peroxidation inhibition assays. Surface tension and  
79 fluorescence spectroscopy experiments showed the capacity of these derivatives to interact with  
80 membrane lipids, with respect to the parent compounds (Trolox and PBN). The nature of the free-  
81 radical scavenger moieties and their location in the membranes were analyzed as key parameters to  
82 rationalize the antioxidant activity of these derivatives, which was supported by molecular dynamics  
83 (MD) simulations.

84

## 85 2. Materials and methods

### 86 2.1. Chemicals

87 Vials of 1,2-dilinoleoyl-*sn*-glycero-3-phosphocholine (DLiPC) powder were purchased from Avanti  
88 Polar Lipids (Alabaster, AL, USA). 2,2'-azo-bis(2-amidinopropane)dihydrochloride (AAPH), 4-(2-  
89 hydroxyethyl)piperazine-1-ethanesulfonic acid (Hepes), ( $\pm$ )-6-hydroxy-2,5,7,8-tetramethylchromane-2-  
90 carboxylic acid (Trolox) and  $\alpha$ -phenyl-*N*-*tert*-butylnitron (PBN) were purchased from Sigma (St. Louis,  
91 MO, USA). FAPBN [29], FATx [29] and FATxPBN [30] were synthesized according to the procedure  
92 previously published.

93 The water used in all assays was purified using a Millipore filtering system (Bedford, MA, USA),  
94 yielding ultrapure water (18.2 M $\Omega$ ×cm). Stock solutions of DLiPC were prepared by dissolving the DLiPC  
95 powder contained in the vials in chloroform or hexane/ethanol 9:1 (v/v) for the preparation of vesicles  
96 and monolayers, respectively. The antioxidants were dissolved in chloroform and ethanol for the  
97 experiments involving vesicles and monolayers, respectively.  $\log P$  values were calculated with the  
98 software ChemSketch version 14.01, Advanced Chemistry Development, Inc. (Toronto, ON, Canada).

99

### 100 2.2. Preparation of DLiPC vesicles

101 DLiPC alone (control assay) and DLiPC/antioxidant mixtures dissolved in chloroform were dried  
102 under a stream of nitrogen and then kept under high vacuum for 2 hours to obtain a solvent-free film.  
103 The dried film was then dispersed in Hepes buffer to obtain a solution of DLiPC multilamellar vesicles  
104 (MLVs) at a concentration of 0.5 mg/mL. Small unilamellar vesicles (SUVs) were obtained by sonicating  
105 MLVs to clarity (3 cycles of 2 min 30 s) with a 500 W titanium probe sonicator at 33 % of the maximal  
106 power from Fisher Bioblock Scientific (Illkirch-Graffenstaden, Grand-Est, France). To limit oxidation due  
107 to heat and light, sonication was performed in the dark and samples were kept in an ice bath. Then,  
108 the SUVs solution was filtered on 0.2  $\mu$ m Acrodisc® from Pall Life Sciences (Port Washington, NY, USA)  
109 to remove titanium particles. To prepare large unilamellar vesicles (LUVs), the MLVs suspension was

110 extruded 19 times at room temperature through a 200 nm nuclepore polycarbonate membrane filter  
111 from Avestin Inc. (Ottawa, Ontario, Canada) with a syringe-type extruder from Avanti Polar lipids Inc.  
112 (Alabaster, AL, USA). SUVs and LUVs size distribution were determined by dynamic light scattering with  
113 a Zetasizer Nano-S from Malvern Instruments (Malvern, Worcestershire, UK). The sizes were on  
114 average 60 nm after sonication and 190 nm after extrusion. The distributions were unimodal.

115

### 116 2.3. Evaluation of the antioxidant efficiency of the fluorinated derivatives

117 The antioxidant efficiency of the non-modified compounds as well as the derivatives was assessed  
118 by evaluating their ability to protect lipid vesicles from oxidation. Because they are frequently used to  
119 evaluate the antioxidant properties of various molecules [32,33], SUVs were chosen to perform these  
120 experiments. DLiPC SUVs (control assay) and DLiPC SUVs containing fluorinated derivatives, Trolox or  
121 PBN at different concentrations were prepared in Hepes buffer as described in section 2.2. The vesicles  
122 were diluted to a final DLiPC concentration of 0.1 mg/mL AAPH, an azo compound widely used in  
123 biochemical reactions to study lipid oxidation [34], was added at a final concentration of 2 mM and the  
124 samples were immediately incubated at 37°C. The heat triggered the degradation of AAPH into peroxy  
125 radicals that initiated the oxidation of the vesicles [35]. As they absorb ultraviolet light between 230  
126 and 235 nm [36] and since they constitute the primary oxidation products of polyunsaturated lipids  
127 [5,37], conjugated dienes were used as an indicator of lipid oxidation. Their appearance was followed  
128 by measuring the absorbance at 234 nm with a Specord S300 UV–VIS spectrophotometer (Jena,  
129 Thuringia, Germany). The values were normalized to zero by subtracting the initial absorbance (0.8 ±  
130 0.2). The results are expressed as percentages of peroxidation, calculated as follows:

$$131 \quad \text{Lipid oxidation (\%)} = \frac{\text{Absorbance}_{\text{sample}}}{\text{Absorbance}_{\text{maxControl}}} * 100 \text{ (eq. 3)}$$

132 The curves were fitted by applying a dose-response model with variable slope with the software  
133 GraphPadPrism version 6.00 for Windows (La Jolla, CA, USA).

134 To further characterize the differences in the antioxidant efficiency of the derivatives, we calculated  
135 the lag time of oxidation as follows:

$$136 \quad lag\ time = time_{10/20\%}^{sample} - time_{10/20\%}^{control} \text{ (eq. 4)}$$

137 where  $time_{10/20\%}$  corresponds to the time required to reach 10 or 20 % of oxidation for the DLiPC SUVs  
138 containing 6,4  $\mu$ M of antioxidant (5 %, mol/mol compared to DLiPC) and for the pure DLiPC vesicles  
139 (control assay).

140

#### 141 2.4. Surface pressure experiments

142 All the experiments were performed at constant temperature ( $21.0 \pm 0.1^\circ\text{C}$ ). The film balance was  
143 built by Nima (Coventry, West Midlands, England) for adsorption experiments on a small Teflon dish.  
144 The dish (surface=19.6  $\text{cm}^2$ ) was equipped with a Wilhelmy-type pressure measuring system. In these  
145 experiments, we used a subphase buffer of 62 mL continuously stirred with a magnetic stirrer spinning  
146 at a rate of 100 rpm. The buffer contained 10 mM of HEPES, 150 mM of NaCl and was adjusted at a pH  
147 of 7.4. To prepare Gibbs monolayers, the compounds – dissolved in ethanol – were injected in the  
148 subphase at two ranges of concentrations: from 1 to 40  $\mu$ M for PBN and Trolox, from 0.0625 to 10  $\mu$ M  
149 for the fluorinated derivatives. Surface tension was recorded during 5 min after the injection.

150 In order to study the adsorption of the compounds to DLiPC monolayers, DLiPC was dissolved in  
151 hexane/ethanol 9:1 (v/v) and spread at the air-water interface to reach the desired surface pressure.  
152 As soon as the initial surface pressure was stabilized ( $\sim 15$  min), the compounds were injected into the  
153 subphase at a final concentration of 50 nM. Their adsorption at the air-lipid buffer interface was then  
154 followed by measuring the variation of surface pressure during 15 minutes. As monolayers of  
155 unsaturated lipids tend to oxidize in contact with air [38,39], we made sure the experiments lasted less  
156 than 40 minutes to avoid a loss of stability due to lipid oxidation. A control experiment was also  
157 performed by injecting ethanol in the subphase, which produced no significant perturbation of the  
158 surface pressure. The binding parameters [40,41] were determined with the calculator available on the



159 following webpage: <http://www.crchudequebec.ulaval.ca/BindingParametersCalculator/>. The kinetics  
160 of adsorption of the antioxidants in DLiPC monolayers was studied by fitting the data to the following  
161 equation [42,43]:

$$162 \quad \ln[(\Pi_{\infty} - \Pi_t)/(\Pi_{\infty} - \Pi_i)] = kt \text{ (eq. 5)}$$

163 where  $\Pi_{\infty}$  designates the equilibrium surface pressure after the injection of the antioxidants in the  
164 subphase of the monolayer,  $\Pi_i$  the initial surface pressure of the monolayer,  $\Pi_t$  the surface pressure at  
165 a time  $t$  and  $k$  the rate coefficient.  $\Pi_{\infty} - \Pi_i$  can also be defined as  $\Delta\Pi$ , which designates the maximum  
166 increase of surface pressure induced by the penetration of the antioxidants in DLiPC monolayers.

167

## 168 2.5. Effect of the antioxidants on the permeability of the membrane

169 The ability of the fluorinated antioxidants to permeabilize DLiPC vesicles was measured with the  
170 calcein release assay. LUVs were chosen instead of SUVs in order to encapsulate larger amounts of  
171 calcein and because the extrusion process allows the elimination of the concentric layers of MLVs  
172 without releasing the encapsulated calcein. DLiPC LUVs were prepared as described in section 2.2 with  
173 HEPES buffer containing 35 mM calcein. Free calcein was separated from encapsulated calcein by gel  
174 filtration on a sepharose 4B column equilibrated with HEPES buffer. Lipids were quantified with the  
175 method developed by Stewart [44]. The solution containing calcein loaded LUVs was diluted to a final  
176 concentration of 10  $\mu$ M lipids in HEPES buffer. Fluorinated antioxidants dissolved in ethanol were  
177 added after 5 min at a ratio of 5 % (mol/mol) compared to DLiPC. Fluorescence measurements were  
178 performed at 21 °C as soon as the LUVs were prepared, immediately after the addition of fluorinated  
179 derivatives and after 30, 60 min and 120 min of incubation with a Varian Cary Eclipse fluorescence  
180 spectrophotometer (Santa Clara, CA, USA). We used excitation and emission wavelengths of 490 and  
181 520 nm respectively. Triton X-100 was added after two hours in order to release the total amount of  
182 encapsulated calcein. The intrinsic fluorescence of fluorinated antioxidants at 520 nm was verified and

183 the values we found were not significant. Release percentages were calculated with the following  
184 equation:

$$185 \quad \text{Calcein release (\%)} = \frac{(F_1 - F_0)}{(F_{Tot} - F_0)} * 100 \text{ (eq.2)}$$

186 where  $F_0$  designates the fluorescence of the LUVs measured in absence of fluorinated derivatives,  $F_1$   
187 the fluorescence of the LUVs measured after addition of fluorinated derivatives and  $F_{Tot}$  the  
188 fluorescence measured after addition of Triton X100 that triggers the release of the encapsulated  
189 calcein.

190

## 191 2.6. Theoretical methodology

192 Two DLiPC membranes made of 128 and 72 lipids each, were created using the membrane bilayer  
193 builder from the CHARMM-GUI server [45]. The membranes were solvated with a hydration number of  
194 35 water molecules per lipid.  $\text{Na}^+$  and  $\text{Cl}^-$  ions were added at a 0.154 M concentration, ensuring the  
195 neutrality of the system. The DLiPC lipids were described using the lipid 11 force field [46]. The force  
196 field parameters for the different compounds (Trolox, anionic Trolox, PBN, FATx, FAPBN, FATxPBN)  
197 were derived from the Generalized Amber Force Field version 2 (GAFF2) [47–49] for all moieties but  
198 the sugars, which were described by the GLYCAM force field [50], using the antechamber package [51].  
199 FATx, FAPBN and FATxPBN were built using a building block approach (*i.e.*, considering the  $\beta$ -D-  
200 galactopyranosyl, 2,6-diaminohexanoyl, 1-amino-dodecafluorooctanyl, Trolox and PBN residues).  
201 Atomic charges were derived from RESP (Restrained fit of Electro Static Potential) based on the  
202 calculations achieved within the Density Functional Theory (DFT) formalism with the IEFPCM-B3LYP/cc-  
203 pVDZ method in diethylether [52], accounting for the chemical environment in the building block  
204 approach. The DFT calculations and the atomic charge fitting were performed with the Gaussian 09,  
205 RevA [53] and R.E.D. III [54] softwares, respectively. The three-point TIP3P water model [55] was used  
206 to describe water molecules. The anionic Trolox was used because, regarding the low pKa of the  
207 carboxylic moiety, Trolox exists in its deprotonated form in the bulk water, and both (neutral and

208 anionic) forms may co-exist in the bilayer. However, regarding insertion in membrane, no significant  
209 differences were observed between the two forms, therefore the results have not been detailed.

210 MD simulations were carried out using CPU-Particle-Mesh Ewald (PME) [56] MD codes available in  
211 Amber16 [57,58], and according to the following procedure: minimization of water molecules prior to  
212 minimization of the entire system to prevent from steric clash; slow thermalization of the water  
213 molecules up to 100 K in the (N,V,T) ensemble for 200 ps; thermalization of the whole system to the  
214 final temperature (310 K) for 500 ps in the (N,P,T) ensemble; equilibration of the system for 5 ns  
215 (N,P,T) MD simulations. Productions of 600 ns (N,P,T) MD simulations were then achieved. PME MD  
216 simulations were carried out using the SHAKE algorithm [59] on H-bonds and a 10 Å non covalent  
217 interaction cut-off for both Coulomb and van der Waals interactions. The temperature was maintained  
218 using the Langevin dynamics [60] with a collision frequency of 1 ps<sup>-1</sup>. Semi-isotropic pressure scaling  
219 with constant surface tension in the xy-plane perpendicular to the membrane normal (z-axis) was used  
220 with Berendsen barostat [61], in which the pressure relaxation time was set to 1 ps.

221 The compounds were inserted in the bulk water of the equilibrated membrane systems, preventing  
222 from steric clash with water molecules. MD simulations of 600 ns were then carried out with all the  
223 compounds; the total MD simulation time for the six derivatives was 3.6 μs. The analyses were  
224 performed along the last 300 ns, which allowed a robust sampling of structural properties, *i.e.*, after  
225 the equilibrium was reached. They were carried out using the cpptraj software [62]. The positions of  
226 the center of mass (COM) or key moieties of the different compounds in membranes are given with  
227 respect to the middle of the bilayer (*i.e.*, z-component of the vector originated at the COM of the lipid  
228 bilayer and pointing towards the COM of the compound). The orientation of the compounds in the  
229 lipid bilayer was assessed by the α-angle between the z-axis and the normal vector(s) defined for each  
230 compound (see supplemental data).

231

232

233 2.7. Statistical analysis

234 Statistical analysis was performed with the software GraphPadPrism version 6.0 for Windows (La  
235 Jolla, CA, USA). Since our samples are small ( $N < 30$ ) and because the values do not follow a normal  
236 distribution, the Mann-Whitney/Wilcoxon test was carried out to compare the combination indexes of  
237 the compounds at low (*i.e.* less than  $1 \mu\text{M}$ ) and high (*i.e.* more than  $1 \mu\text{M}$ ) concentrations.  $p$  values <  
238 0.05 were considered as statistically significant.

239

### 3. Results

#### 3.1. Fluorinated derivatives are efficient to limit lipid peroxidation

In order to evaluate the antioxidant efficiency of the compounds, DLiPC SUVs containing the parent compounds or the fluorinated derivatives were prepared and incubated with AAPH. Oxidation percentages were calculated with eq.3 as described in section 2.3 and reported over time. In absence of antioxidant we observed an immediate increase of the percentages of oxidation. The exponential phase was reached after 10 min and the percentages of oxidation kept increasing until reaching a plateau at 60 min (Fig. 2A). This increase is due to the formation of conjugated dienes which are the primary products of lipid oxidation [5,37], and which in turn drive the beginning of the kinetics. Consequently, after 80 min, the percentages of lipid oxidation in absence of antioxidants decreased, as the oxidation process continued beyond the conjugated dienes stage. Namely, conjugated dienes were progressively replaced by secondary peroxidation products that are not detected at 234 nm. With increasing concentrations of FATxPBN, oxidation percentages firstly increased slower than the control, which suggests an ability of FATxPBN to slow down the oxidation process. The exponential phase started after 60 min, at a higher level of oxidation than the control, causing the oxidation percentages to go over 100 % after 100 min. Also, we noticed a gradual decrease of oxidation percentages, showing a dose-dependent antioxidant efficiency of FATxPBN (Fig. 2A). Similar tendencies, although they were less pronounced, were observed with Trolox, FATx and FAPBN (Fig. S1).

To better compare the antioxidant efficiencies, we reported the percentages of oxidation at 80 min (*i.e.*, the time required to reach the plateau in the absence of antioxidant) versus the antioxidant concentration (Fig. 2B-F). For FATxPBN and FATx, concentrations ranging from 1.6 to 6.4  $\mu\text{M}$  appeared sufficient to reach the maximal antioxidant efficiency. FAPBN was significantly less efficient as saturation was reached with a concentration of 38.4  $\mu\text{M}$ . No significant antioxidant efficiency was observed for PBN, even at high concentrations (*i.e.* 25.6-38.4  $\mu\text{M}$ ). Trolox, FATxPBN, FATx and FAPBN presented  $\text{IC}_{50}$  (concentration required to half-reduce the oxidation in absence of antioxidant) values of

265 4.0, 0.6, 0.9, and 29.5  $\mu\text{M}$ , respectively, whereas no  $\text{IC}_{50}$  could be determined for PBN. The better  
266 capacity of Trolox to inhibit lipid oxidation in comparison to PBN agrees with previous work [30],  
267 where we showed that Trolox was more efficient than PBN to scavenge  $\text{ABTS}^{+\bullet}$  radicals. In the present  
268 work, all three fluorinated derivatives exhibited lower  $\text{IC}_{50}$  than their parent compounds. Indeed,  
269 FATxPBN and FATx exhibited  $\text{IC}_{50}$  values  $\sim 5$  times lower than Trolox (0.6 and 0.9  $\mu\text{M}$  versus 4.0  $\mu\text{M}$ ).  
270 FAPBN displayed an  $\text{IC}_{50}$  of 29.5  $\mu\text{M}$  while PBN presented no  $\text{IC}_{50}$ .

271 To better compare the most efficient derivatives (*i.e.* FATxPBN and FATx), we determined the lag  
272 times (Fig. 3), which represent the time required to reach either 10 or 20 % lipid peroxidation for DLiPC  
273 SUVs containing 5 % (mol/mol, concentration at which the antioxidant efficiency was optimal) of  
274 antioxidant. Except for PBN and FAPBN at 20% oxidation ( $1.5 \pm 2.0$  and  $6.0 \pm 1.0$  min, respectively), the  
275 lag times of the fluorinated antioxidants did not significantly differ compared to that of the parent  
276 compounds. In the case of FATxPBN, the lag time to reach 10 and 20 % of oxidation was significantly  
277 higher than the two other derivatives, suggesting that this molecule has a different kinetic inhibition  
278 process which efficiently delayed the oxidation process. These data confirmed a significantly improved  
279 antioxidant efficiency of the fluorinated antioxidants with respect to the parent compounds.

280

## 281 3.2. Interactions of the antioxidants with DLiPC membranes

### 282 3.2.1. Interfacial behavior of the antioxidants

283 To characterize the amphiphilicity of the compounds and gain information on their hydrophobic  
284 properties, we measured their ability to adsorb at the air-buffer interface. Increasing concentrations  
285 were injected in the subphase and the surface tension was recorded continuously to assess the  
286 formation of a Gibbs monolayer at the interface. The injection of 1, 5, 10, 20 and 30  $\mu\text{M}$  of Trolox and  
287 PBN exhibited only a poor effect on the surface pressure as the variations of surface pressure ( $\Delta\Pi$ )  
288 recorded were ranging between 0 and 3 mN/m (Fig. S2). Conversely, the fluorinated antioxidants  
289 presented a high surface activity since the injection of 0.1  $\mu\text{M}$  was sufficient to observe a significant

290 surface activity (Fig. 4). A maximal surface activity of  $\sim 40$  mN/m was reached at only  $1 \mu\text{M}$  for  
291 FATxPBN and FATx and at  $3 \mu\text{M}$  for FAPBN, indicating that both FATxPBN and FATx are more  
292 hydrophobic than FAPBN. Higher concentrations (*i.e.*  $5$  and  $10 \mu\text{M}$ ) were also tested and the  $\Delta\Pi$  values  
293 remained close to  $40$  mN/m, reflecting the formation of stable monolayers at the air-water interface.

294 The micellization was previously studied and results showed that while the parent compounds  
295 exhibit no critical micellar concentration (cmc); FATxPBN and FAPBN have cmc values of  $10$  and  $51 \mu\text{M}$ ,  
296 respectively [30]. In accordance with the cmc values, the three fluorinated antioxidants exhibited  $\log P$   
297 values significantly higher than the parent compounds (Fig. 1). The higher hydrophobicity of Trolox  
298 over PBN was clearly observed, with  $\log P$  values of  $3$  and  $1.3$ , respectively. This was also observed  
299 when comparing FATx and FAPBN that present  $\log P$  values of  $3.8$  and  $2$ , respectively. The same  
300 tendency was observed with the experimentally-determined  $\log k'_w$  values previously reported [30].  
301 FATxPBN and FATx exhibited  $\log k'_w$  values  $\sim 5$  times higher than Trolox when that of FAPBN was  $3$   
302 times higher than PBN. This confirms the strong contribution of the perfluorinated chain to the overall  
303 hydrophobicity of amphiphilic molecules leading therefore to low cmc values [63]. Altogether, the  
304 higher hydrophobic character of the fluorinated antioxidants compared to the parent compounds  
305 suggest a better ability to interact with the hydrophobic core of the membrane, which may explain the  
306 more pronounced antioxidant efficiency previously observed.

### 307 3.2.2. Interactions with an unsaturated phospholipid

308 Oxidative stress as well as Gibbs monolayers experiments revealed significant discrepancies  
309 regarding the hydrophobic properties of fluorinated antioxidants as well as their ability to prevent  
310 membrane lipid oxidation. To evaluate their ability to interact with membranes and understand those  
311 differences of efficiency, we performed adsorption assays at lipid monolayers. DLiPC monolayers were  
312 prepared at different initial pressures and the derivatives were injected into the subphase. The  
313 variation of pressure was recorded to evaluate the ability of the derivatives to modify the surface  
314 activity of the monolayer. Due to the strong surface activity of the fluorinated antioxidants and the

315 formation of aggregates above the cmc, the derivatives were injected in the subphase of the  
316 monolayers at a final concentration of 0.05  $\mu\text{M}$ ; a concentration significantly lower than their cmc at  
317 which they all presented a negligible surface activity (see Fig. 4). The variation of pressure ( $\Delta\Pi$ ) was  
318 reported over the initial surface pressure ( $\Pi_i$ ) in order to determine the binding parameters of the  
319 compounds [40]. The injection of the parent compounds had little effect on the surface pressure, as  
320  $\Delta\Pi$  remains below 3 mN/m independently of the initial pressure (Fig. S3). Conversely, the injection of  
321 the fluorinated antioxidants (Fig. 5A-C) caused an immediate increase of the surface pressure and  
322  $\Delta\Pi$  decreased when the initial pressure was increased. The synergy factor was calculated by adding  
323 one to the value of the slope of the regression curve (Table 1). All the compounds presented positive  
324 synergy factors, indicating a favorable binding of the compounds to DLiPC membranes. Also, linear  
325 regression provided the maximal insertion pressure (MIP), highlighting the highest pressure at which  
326 fluorinated antioxidants can penetrate monolayers [40]. As reported in Table 1, FATxPBN, FATx and  
327 FAPBN exhibited MIPs of 52.2, 48.6 and 37.6 mN/m, respectively. Because all the MIPs are higher than  
328 the average lateral pressure in biological membranes –  $\sim 30\text{mN/m}$  [64] –, one can conclude that  
329 fluorinated antioxidants can penetrate bilayers under physiological conditions.

330 Since the lower MIP of FAPBN may indicate a less pronounced affinity for DLiPC monolayers [41],  
331 another parameter named  $\Delta\Pi_0$  can be determined to gain information on the ability of the fluorinated  
332 antioxidants to partition into DLiPC membranes [40].  $\Delta\Pi_0$  is determined by performing an  
333 extrapolation on Fig. 5 from an initial surface pressure of 0 mN/m and corresponds to the intersection  
334 of the linear regression with the y-axis. We performed an extrapolation at the average lateral pressure  
335 of membranes – *i.e.* 30 mN/m [64] – to determine  $\Delta\Pi_{30}$ , which is related to the quantity of compound  
336 associated to the monolayer. As reported in Table 1, FATxPBN and FATx exhibited  $\Delta\Pi_{30}$  values  $\sim 4$   
337 times higher than FAPBN (10.0 and 9.0 versus 2.1 mN/m), indicating that greater amounts of FATxPBN  
338 and FATx spontaneously penetrated the membrane in comparison to FAPBN.



339 Fitting the data recorded at 30 mN/m with eq.5 allowed us to determine the rate of penetration ( $k$ )  
340 of the fluorinated antioxidants in DLiPC monolayers at the average lateral pressure of membranes, as  
341 described in [43]. The plot yielded three linear regions (Fig. 6). The first linear region corresponds to  
342 the stabilization of the lipid monolayer in absence of antioxidant, the second one to the penetration of  
343 the antioxidants in the monolayer and the third one to the rearrangement between the lipids and the  
344 antioxidants in the monolayer [42]. The rate of penetration was determined by calculating the slope of  
345 the second linear region (Table 1). FATx and FATxPBN present  $k$  values twice as important as FAPBN,  
346 showing they penetrate the membrane faster than FAPBN. This result, in accordance with the MIP and  
347  $\Delta\Pi_{30}$  values, underlines the effect of the fluorinated chain, which has increased the affinity of the  
348 parent compounds for DLiPC.

349 Although our results indicate the fluorinated antioxidants interact favorably with DLiPC membranes,  
350 we are aware that hydrogenated and fluorinated lipids may not be miscible [65,66]. Nevertheless,  
351 there is a general consensus among the community that fluorinated and hydrogenated surfactants are  
352 miscible, however whether they do mix completely or only partially is still subject to debate [67].  
353 Several reports in the literature suggests various degrees of miscibility between fluorinated and  
354 hydrogenated detergents and therefore different scenarios of mixing leading to: (i) the formation of  
355 one type of mixed micelles [68]; (ii) the demixing of the two leading to the coexistence of two types of  
356 micelles [69] or (iii) both, depending on the mixing ratio [70,71]. In our case, it is worth mentioning  
357 that FATx and FATxPBN reached their maximum antioxidant efficiency at concentrations ranging from  
358 1.6 to 6.4  $\mu\text{M}$  (*i.e.* molar ratios ranging from 1.25 to 5 % in comparison to DLiPC, Fig. 2D-E). These  
359 ratios are sufficiently low to expect only slightly perturbations of the membrane and prevent miscibility  
360 issues. Conversely, FAPBN was not efficient at low concentrations and 38.4  $\mu\text{M}$  (*i.e.* 30 % molar ratio)  
361 was required to reach a significant antioxidant efficiency (Fig. 2F). The low antioxidant efficiency  
362 combined with the poor affinity for membranes as well as the possible impact of a high concentration

363 in membranes highlight the fact that FAPBN presents less interest than the two other fluorinated  
364 antioxidants.

### 365 3.3. The fluorinated antioxidants do not modify the membrane's structure

366 We performed calcein release experiments to evaluate the impact of the fluorinated antioxidants  
367 on the membrane integrity. DLiPC LUVs containing calcein were prepared and the fluorinated  
368 antioxidants were added to the samples and fluorescence was measured during 2 hours to evaluate  
369 the calcein leakage. The fluorinated antioxidants were introduced at a 5 % molar ratio in comparison to  
370 DLiPC since at this concentration the antioxidant effect we observed was maximal in the case of  
371 FATxPBN and FATx (see Fig. 2). In order to stay consistent, FAPBN was tested with the same  
372 concentration although its antioxidant efficiency was limited at low concentrations. Tests of  
373 permeability with higher concentrations would have not been relevant from a physiological point of  
374 view since an antioxidant is supposed to be efficient at low concentrations [72]. In all cases, the  
375 addition of the derivatives caused a weak leakage from the LUVs, with however a percentage of  
376 leakage below 5 % during the entire experiment (Fig. S4). The addition of Triton X100 after two hours  
377 caused a significant increase of the fluorescence intensity due to the release of the total amount of  
378 encapsulated calcein. Because the injection of the derivatives did not significantly modify calcein  
379 leakage, we concluded that their insertion has no significant effect on the structure of the membrane.

380 Regarding the interactions between fluorinated surfactants and phospholipids, it is generally  
381 admitted that fluorinated surfactants do not solubilize membranes and therefore they have been  
382 successfully used to solubilize hydrophobic proteins in the presence of liposomes acting as chaperones  
383 [73]. Recently, a phosphocholine based fluorinated derivative (F6OPC) with a perfluorohexyl chain  
384 similar to that of FATxPBN was found to partition into POPC bilayers without inducing the solubilization  
385 of preformed vesicles [74]. Conversely, Frotscher and co-workers observed the complete solubilization  
386 of lipid vesicles after incubation with a fluorinated surfactant bearing the same perfluorohexyl chain  
387 and a maltoside polar head group (F6OM) [75]. Our assays did not reveal any significant modification

388 of the permeability of the membrane, indicating that the fluorinated antioxidants tested here did not  
389 solubilize the membrane at the concentration they are the most effective. This is very likely due to the  
390 very low concentration (physiologically more relevant) used in the present study (5 % mol, *i.e.* 0.5  $\mu$ M)  
391 compared to the 2 mM used by Frotscher and co-workers.

392

#### 393 3.4. MD simulations to support positioning of the fluorinated antioxidants in DLiPC membranes

394 Each derivative was placed at different positions at the beginning of the MD simulations. It is worth  
395 noting that all simulations, each molecule reached similar equilibrium position in the membrane. In  
396 other words, when starting from the bulk water all the compounds inserted into the DLiPC lipid  
397 bilayers. The preferred (equilibrium) position of the center of mass (COM) of Trolox and PBN were just  
398 below the polar head group region in close contact with the phosphates and to a less extent with the  
399 choline moieties (14.0 and 13.6 Å for both compounds, respectively from the middle of the bilayer, see  
400 Table 2 and Fig. S6 for the radial distribution function). The fluorinated antioxidants also partition just  
401 below the polar head group region, the COM being at 14.3, 14.7 and 13.7 Å from the middle of the  
402 bilayer for FATx, FAPBN and FATxPBN, respectively (Table 2). The different equilibrium positions  
403 obtained from the MD simulations were fully consistent with the chemical structures of these  
404 amphiphilic derivatives, as the different moieties drive the preferred location. Namely, from one side,  
405 both  $\beta$ -D-Galactose and gluconic acid moieties strongly anchor the derivatives to the choline and to the  
406 phosphate groups (*ca.* 16.5 and 20.0 Å for both moieties, respectively, from the middle of the bilayer)  
407 by electrostatic and H-bonding interactions (Fig. 6). From another side, the fluorinated chain lines up  
408 along the DLiPC lipid chains (COM of the fluorinated chain ranging from 8.2 to 10.4 Å, see Table 2),  
409 anchoring the derivatives into the membrane (Fig. 6). In the case of the fluorinated antioxidants, the  
410 Trolox and PBN moieties fluctuate below the polar head group region (ranging from 13.8 to 15.7 Å  
411 from the middle of the bilayer, see Table 2) with a preferred orientation parallel to the surface (Fig. S7)  
412 in close contact with the phosphates, as for the parent Trolox and PBN derivatives.

413 Interestingly, in the case of FAPBN, the MD simulations, which were performed to ensure a  
414 sufficient conformational sampling, highlighted the existence of a second (minor) conformer inside the  
415 membrane. In this conformer, the PBN moiety was driven deeper in the membrane (9.0 Å from the  
416 middle of the bilayer, see Table 2), in close contact with the fluorinated chain (Fig. 6D). This minor  
417 conformer corresponds to a 3-dimensional molecular arrangement which has been observed during  
418 short-lasting period along the MD simulation time. In this conformer, PBN is lining up along the  
419 fluorinated chain (Fig. 6D), whereas in the major conformer (seen during long-lasting period of the MD  
420 simulations), PBN is far apart from the fluorinated chain. Conversely, no similar alignment of the Trolox  
421 moiety and the fluorinated chain (in FATx and FATxPBN) was observed throughout the whole MD  
422 simulations, even though some initial geometries were driven to put these two moieties were in close  
423 contact. As a consequence, no intramolecular interactions between the Trolox and PBN moieties were  
424 observed in FATxPBN throughout the whole MD simulations.

425

#### 426 **4. Discussion**

427 The antioxidant assays conducted in this work highlight that the three fluorinated antioxidants are  
428 much more efficient than the parent compounds PBN and Trolox. This is consistent with various other  
429 studies on hybrid antioxidants, which showed how the chemical combination of two antioxidant  
430 moieties enhances the activity with respect to both moieties taken separately [26–28]. Along the same  
431 line to maximize lipid peroxidation activity, we previously conducted a similar study by combining PBN  
432 and cholesterol within amphiphilic derivatives [76]. By using similar experimental setups than in the  
433 present study, we showed these cholesteryl-PBN derivatives displayed enhanced hydrophobic and  
434 antioxidant properties in comparison to the parent compound PBN, as dynamic light scattering and  
435 oxidative stress experiments evidenced a stronger ability of cholesteryl-PBNs to stabilize the structure  
436 of the vesicles and to preserve them from the swelling due to the oxidation process. The molecules  
437 tested in this work, in particular FATxPBN and FATx, present lower IC<sub>50</sub> values than the cholesteryl-

438 PBNs, which underline a stronger ability to prevent lipid oxidation, as expected due to the presence of  
439 the Trolox moiety.

440 We observed significant discrepancies between the fluorinated antioxidants, as both FATxPBN and  
441 FATx exhibited  $IC_{50}$  values that are 49 and 33 times lower (higher activity) than FAPBN, respectively  
442 (see Fig. 2). The differences observed between FAPBN and the other two fluorinated antioxidants can  
443 be rationalized by a lower affinity to lipid (slightly lower hydrophobicity, see  $\log P$  on Fig. 1) of the  
444 former parent compound (*i.e.* PBN) and by the absence of the Trolox moiety in this derivative. The  
445 scavenging mechanisms of both Trolox and PBN are different (most probably hydrogen atom  
446 abstraction and adduct formation – spin trap –, respectively), which makes the former derivative a  
447 much better free radical scavenger. Concomitantly, the amphiphilic feature of the derivatives finely  
448 tunes the capacity for lipid peroxidation inhibition, by ensuring a positioning in the membrane below  
449 the polar head groups, in close contact with the oxidation process (*i.e.*, as close as possible from  
450 unsaturation). At this preferred location, the derivatives are likely to inhibit both the initiation stage or  
451 the propagation stage for lipid chains which can adopt a transient snorkel-like shape [77,78] of lipid  
452 peroxidation. Also, it is well-known that location of the antioxidants in close contact to the  
453 unsaturations of the phospholipid acyl chains favors a better inhibition of lipid peroxidation [79]. The  
454  $\log P$  values suggest that the higher the hydrophobicity, the higher the maximal insertion pressure and  
455 the deeper the molecules penetrate into the membrane (Fig. S5 A-B). In accordance with our  
456 observations, Azouzi and co-workers recently reported that serotonin has the ability to bind and  
457 protect DLiPC enriched membranes from oxidation [80], due to frequent interactions between  
458 serotonin and phospholipid acyl chains, which might inhibit the propagation stage of lipid  
459 peroxidation.

460 Interestingly, PBN exhibited no lipid peroxidation inhibition whereas an  $IC_{50}$  was measured with  
461 FAPBN. As seen from the MD simulations and highly expected from their chemical nature, both PBN  
462 itself and the PBN moiety in the major conformer of FAPBN lie at almost the same preferred position.

463 Therefore, a highly plausible explanation of the better activity of FAPBN with respect to PBN is  
464 assigned to an anchoring effect, which is attributed to the fluorinated chain which better constrain  
465 (anchor) the positioning of the PBN moiety in the membrane for FAPBN. This can in turn makes the  
466 PBN moiety more efficient as a spin trapper. Although hardly directly reachable by experimental  
467 techniques, the explanation of the measurable  $IC_{50}$  value for FAPBN is likely due to its amphiphilic  
468 chemical nature, which allows this anchoring effect in close contact to the region where lipid oxidation  
469 occurs. A secondary explanation might be due to the existence of the second (minor) FAPBN  
470 conformer (Fig. 7D), in which the PBN moiety may even spend some time deeper in the bilayer to  
471 inhibit lipid peroxidation more efficiently than PBN alone, however not as efficient as both FATxPBN  
472 and FATx due to a much less efficient free radical scavenging capacity.

473 FATx is 33 times more active than FAPBN, which is mainly attributed to the nature of the  
474 antioxidant moiety and not to positioning. Indeed, Trolox is a much more efficient free radical  
475 scavenger than PBN, while the MD simulations suggest that both moieties are positioned in the same  
476 membrane region, in close contact with the polar head group region due to their relatively hydrophilic  
477 and H-bonding donor/acceptor nature. With an  $IC_{50}$  of 0.6  $\mu$ M, FATxPBN has shown the highest  
478 antioxidant activity among all three fluorinated antioxidants. Since FATxPBN presents an  $IC_{50}$  lower  
479 than the average of FATx and FAPBN, the combination of Trolox and PBN moieties on a same carrier  
480 was hypothesized to have created a synergistic antioxidant effect. To confirm or infirm this hypothesis,  
481 the activity of FATx and FAPBN was more thoroughly compared to that of FATxPBN to decipher  
482 whether the combination result in simple additive, supra-additive (synergistic) or infra-additive  
483 (inhibition of one agent by the other) effects. Both FATx and FAPBN are considered here as two  
484 separated antioxidant agents engaged in a similar skeleton; *i.e.*, an antioxidant moiety linked to a  
485 perfluorinated chain and a sugar moiety. To address this issue, the combination index (CI) of FATx and  
486 FAPBN was determined based on the Chou and Talalay method [81]. As one can see in Table 3, at low  
487 concentrations (*i.e.*, 0.4 to 0.8  $\mu$ M) the combination of FATx and FAPBN creates a synergistic

488 antioxidant effect as CI values are lower than 1. This effect disappears when the concentrations are  
489 increased as with concentrations ranging from 1.6 to 38.4  $\mu\text{M}$ , the CI values are higher than 1,  
490 suggesting an infra-additive effect (*i.e.* inhibition between both antioxidant moieties). The statistical  
491 analysis evidenced significant differences ( $p < 0.05$ ) between the CI values of the low (0.4 to 0.8  $\mu\text{M}$ )  
492 and the high concentrations (1.6 to 38.4  $\mu\text{M}$ ), which underlines the presence of a synergistic effect at  
493 low concentrations. Similar trends (Table. S1) were observed by multiplying the percentages of lipid  
494 oxidation of FATx and FAPBN and comparing them to those of FATxPBN according to the Berenbaum  
495 method [82,83], leading to similar conclusions.

496 Several researchers have reported on synergistic effects created by combining different antioxidant  
497 moieties. For instance, it has been reported that the combination of  $\beta$ -carotene and  $\alpha$ -tocopherol  
498 results in a better protection of rat liver microsomes from oxidative stress [84]. Recently, Trolox has  
499 been mixed with caffeic acid phenethyl ester (CAPE) to create a synergistic antioxidant effect [85],  
500 which was attributed to weak interactions (hydrogen bonds) between Trolox and CAPE. Trolox has also  
501 been combined to nitrones to create nitrone derivatives of Trolox [86], which revealed more efficient  
502 *in vitro* and *in vivo* activities against lipid peroxidation and ischemia with respect to the parent  
503 compounds. Synergism between antioxidants can proceed through different mechanisms like sacrificial  
504 oxidation [87], regeneration or other mechanisms [88]. In the case of sacrificial oxidation, one  
505 antioxidant protects the other by free radical scavenging, while for regeneration, one antioxidant is  
506 oxidized to renew the second one. An extensively-described and typical example of regeneration is the  
507 interaction between vitamin E and vitamin C [89]. Other researchers attempted to combine, in a single  
508 molecule, different types of antioxidants to favor synergistic effects. For instance, lipoic acid has been  
509 combined to Trolox [26] as well as a nitric oxide synthase inhibitor [28] with the objective to obtain  
510 greater protective effects. Preliminary experiments on biological systems highlighted that these  
511 divalent antioxidants have better abilities to prevent neuronal damage caused by glutamate and  
512 oxidation of rat microsomal membrane lipids. Recently, Vavrilokova and co-workers, through

513 enzymatic reactions, combined silybin to ascorbic acid, Trolox alcohol or tyrosol to obtain novel  
514 divalent antioxidants [27]. Among all the derivatives, the derivative combining silybin to ascorbic acid  
515 showed the highest ability to protect rat microsomes from lipid peroxidation. Durand and co-workers  
516 previously reported the synthesis of PBNLP, a divalent antioxidant bearing a PBN and a lipoic acid  
517 moiety [90]. No synergistic antioxidant effect was observed as PBNLP and its individual constituents  
518 showed a similar ability to protect red blood cells from AAPH-induced hemolysis. However, the  
519 combination of the two moieties on the same carrier strongly diminished the antagonist effect  
520 observed between the individual derivatives.

521 In the case of FATxPBN, no intramolecular interactions between both antioxidant (Trolox and PBN)  
522 moieties were observed by MD simulations, which is fully consistent with the amphiphilic nature of the  
523 molecule and the chemical nature of the different moieties. This precludes regeneration effect within  
524 the same molecule. However, the compounds are likely to accumulate in a narrow region and  
525 regarding the similar depth of insertion of both Trolox and PBN moieties, intermolecular interactions  
526 are likely to occur. This could favor a regeneration process. This appears possible at relatively low  
527 concentration, *i.e.*, below 0.8  $\mu\text{M}$ , as seen by the experimental results. This may correspond to greater  
528 local concentration due to partitioning in membrane. In this case small non-covalent clusters can be  
529 formed. At higher concentration values this effect disappears (Table 3), most probably due to the  
530 formation of higher-order aggregates, in which less antioxidant moieties are available. Also, the ability  
531 of FATxPBN to strongly delay lipid oxidation compared to the other antioxidants (see Fig. 3) suggests  
532 that this derivative combines the retarding effect of PBN [91] with the free radical scavenging capacity  
533 of Trolox [92], thus creating a synergistic effect by retardation. At first, the PBN moiety seems to delay  
534 the oxidation during 60 min, as percentages of oxidation of the SUVs are the same, regardless of the  
535 concentration of FATxPBN (see Fig. 2A). Then, the dose-dependent antioxidant efficiency observed  
536 might be attributed to the Trolox moiety, as FAPBN is only slightly efficient against AAPH-induced  
537 oxidation (see Fig. 2F).





539 **5. Conclusion**

540 The present work is in line with the strategy aiming at grafting two antioxidant moieties on the  
541 same carrier to enhance the global antioxidant action with a nanoscale fine tuning. The key role of the  
542 amphiphilic feature of this series of fluorinated antioxidants bearing Trolox and/or PBN moieties was  
543 studied in terms of interaction with membranes. The presence of the perfluorinated chain increases  
544 hydrophobicity, allowing these derivatives to form monolayers at the air-water interface. Because of  
545 higher hydrophobicity, they are anchored to the DLiPC membranes, with a greater antioxidant activity  
546 against AAPH-induced lipid oxidation. Interestingly, although PBN is inefficient, its combination with a  
547 Trolox moiety on the same carrier creates a synergistic effect that improves the global antioxidant  
548 efficiency. Thanks to a dual mode of action, such hybrid antioxidants are very promising molecules for  
549 a wide range of applications in cosmetic, food and pharmaceutical industries by lowering the usual  
550 concentrations of antioxidant required to efficiently prevent lipid oxidation.

551 **Author's contributions**

552 G.D and S.M conceived this research. M.R synthesized the fluorinated antioxidants. L.S and A.M.G.G  
553 performed the experiments with model membranes. B.C and F.D.M designed and performed MD  
554 simulations. B.C, F.D.M and P.T analyzed the theoretical data. L.S analyzed the experimental data and  
555 wrote the article. P.T, G.D and S.M formatted the manuscript.

556

557 **Acknowledgements**

558 L. Socrier was the recipient of a PhD scholarship from the French "Ministère de l'enseignement  
559 supérieur de la recherche et de l'innovation". Dr M. Rosselin was the recipient of a fellowship from the  
560 "Provence Alpes Côte d'Azur" regional council. The "Centre national de la recherche scientifique  
561 (CNRS)", the "Université de Technologie de Compiègne" and the "Université d'Avignon et des Pays du  
562 Vaucluse" are gratefully acknowledged for providing facilities and financial support. P. Trouillas, B.  
563 Chantemargue and F. Di Meo thank CALI, "Nouvelle Aquitaine" regional council and the "Institut  
564 national de la santé et de la recherche médicale (INSERM)". P. Trouillas thanks the Czech Science  
565 Foundation (P208/12/G016) and the National Program of Sustainability from the Ministry of Youth,  
566 Education and Sports of the Czech Republic (LO1305).

567

568 **Conflict of interest**

569 The authors declare no conflict of interest.

570

571 **Supporting material**

572 Supporting material (7 figures and 1 table) can be found at

573

574 **6. References**

- 575 [1] K. Apel, H. Hirt, Reactive oxygen species: metabolism, oxidative stress, and signal transduction.,  
576 Annu. Rev. Plant Biol. 55 (2004) 373–99. doi:10.1146/annurev.arplant.55.031903.141701.
- 577 [2] H.J. Forman, M. Torres, Reactive oxygen species and cell signaling: respiratory burst in  
578 macrophage signaling., Am. J. Respir. Crit. Care Med. 166 (2002) S4–8.  
579 doi:10.1164/rccm.2206007.
- 580 [3] W. Dröge, Free Radicals in the Physiological Control of Cell Function, Physiol. Rev. 82 (2002) 47–  
581 95. doi:10.1152/physrev.00018.2001.
- 582 [4] J. Pincemail, M. Meurisse, R. Limet, J.O. Defraigne, Espèces oxygénées activées, antioxydants et  
583 cancer, Vaiss. Coeur, Poumons. 4 (1999) 2–5. [http://www.vcp-bhl.be/fr/home?tk\\_id=nosign](http://www.vcp-bhl.be/fr/home?tk_id=nosign).
- 584 [5] R. Wheatley, Some recent trends in the analytical chemistry of lipid peroxidation, TrAC Trends  
585 Anal. Chem. 19 (2000) 617–628. doi:10.1016/S0165-9936(00)00010-8.
- 586 [6] R. Sultana, M. Perluigi, D.A. Butterfield, Lipid peroxidation triggers neurodegeneration: A redox  
587 proteomics view into the Alzheimer disease brain, Free Radic. Biol. Med. 62 (2013) 157–169.  
588 doi:10.1016/j.freeradbiomed.2012.09.027.
- 589 [7] G. Kojda, Interactions between NO and reactive oxygen species: pathophysiological importance  
590 in atherosclerosis, hypertension, diabetes and heart failure, Cardiovasc. Res. 43 (1999) 562–571.  
591 doi:10.1016/S0008-6363(99)00169-8.
- 592 [8] G. Waris, H. Ahsan, Reactive oxygen species role in the development of cancer and various  
593 chronic conditions, J. Carcinog. 5 (2006) 14. doi:10.1186/1477-3163-5-14.
- 594 [9] J. Pardeike, A. Hommoss, R.H. Müller, Lipid nanoparticles (SLN, NLC) in cosmetic and  
595 pharmaceutical dermal products, Int. J. Pharm. 366 (2009) 170–184.  
596 doi:10.1016/j.ijpharm.2008.10.003.
- 597 [10] A.V.S. Perumalla, N.S. Hettiarachchy, Green tea and grape seed extracts — Potential applications  
598 in food safety and quality, Food Res. Int. 44 (2011) 827–839. doi:10.1016/j.foodres.2011.01.022.

- 599 [11] J. Fernández, J.A. Pérez-Álvarez, J.A. Fernández-López, Thiobarbituric acid test for monitoring  
600 lipid oxidation in meat, *Food Chem.* 59 (1997) 345–353. doi:10.1016/S0308-8146(96)00114-8.
- 601 [12] R. Khanum, H. Thevanayagam, Lipid peroxidation: Its effects on the formulation and use of  
602 pharmaceutical emulsions, *Asian J. Pharm. Sci.* 12 (2017) 401–411.  
603 doi:10.1016/j.ajps.2017.05.003.
- 604 [13] A.M. Pisoschi, A. Pop, The role of antioxidants in the chemistry of oxidative stress: A review, *Eur.*  
605 *J. Med. Chem.* 97 (2015) 55–74. doi:10.1016/j.ejmech.2015.04.040.
- 606 [14] V.J. Forrest, Y.-H. Kang, D.E. McClain, D.H. Robinson, N. Ramakrishnan, Oxidative stress-induced  
607 apoptosis prevented by trolox, *Free Radic. Biol. Med.* 16 (1994) 675–684. doi:10.1016/0891-  
608 5849(94)90182-1.
- 609 [15] V.F. Sagach, M. Scrosati, J. Fielding, G. Rossoni, C. Galli, F. Visioli, The water-soluble vitamin E  
610 analogue Trolox protects against ischaemia/reperfusion damage in vitro and ex vivo. A  
611 comparison with vitamin E, *Pharmacol. Res.* 45 (2002) 435–439. doi:10.1006/phrs.2002.0993.
- 612 [16] L.R.C. Barclay, M.R. Vinqvist, Membrane peroxidation: Inhibiting effects of water- soluble  
613 antioxidants on phospholipids of different charge types, *Free Radic. Biol. Med.* 16 (1994) 779–  
614 788. doi:10.1016/0891-5849(94)90193-7.
- 615 [17] N.J. Miller, C. Rice-Evans, M.J. Davies, V. Gopinathan, A. Milner, A Novel Method for Measuring  
616 Antioxidant Capacity and its Application to Monitoring the Antioxidant Status in Premature  
617 Neonates, *Clin. Sci.* 84 (1993) 407–412. doi:10.1042/cs0840407.
- 618 [18] R. van den Berg, G.R.M.M. Haenen, H. van den Berg, A. Bast, Applicability of an improved Trolox  
619 equivalent antioxidant capacity (TEAC) assay for evaluation of antioxidant capacity  
620 measurements of mixtures, *Food Chem.* 66 (1999) 511–517. doi:10.1016/S0308-8146(99)00089-  
621 8.
- 622 [19] E. Finkelstein, G.M. Rosen, E.J. Rauckman, Spin trapping of superoxide and hydroxyl radical:  
623 Practical aspects, *Arch. Biochem. Biophys.* 200 (1980) 1–16. doi:10.1016/0003-9861(80)90323-9.

- 624 [20] R.A. Floyd, K. Hensley, M.J. Forster, J.A. Kelleher-Andersson, P.L. Wood, Nitrones, their value as  
625 therapeutics and probes to understand aging, *Mech. Ageing Dev.* 123 (2002) 1021–1031.  
626 doi:10.1016/S0047-6374(01)00385-2.
- 627 [21] S. Doblaz, D. Saunders, P. Kshirsagar, Q. Pye, J. Oblander, B. Gordon, S. Kosanke, R.A. Floyd, R.A.  
628 Towner, Phenyl-tert-butyl nitronone induces tumor regression and decreases angiogenesis in a C6  
629 rat glioma model, *Free Radic. Biol. Med.* 44 (2008) 63–72.  
630 doi:10.1016/j.freeradbiomed.2007.09.006.
- 631 [22] R.A. Floyd, H.C.C.F. Neto, G.A. Zimmerman, K. Hensley, R.A. Towner, Nitronone-based therapeutics  
632 for neurodegenerative diseases: Their use alone or in combination with lanthionines, *Free Radic.*  
633 *Biol. Med.* 62 (2013) 145–156. doi:10.1016/j.freeradbiomed.2013.01.033.
- 634 [23] M.I. Ayuso, M. Chioua, E. Martínez-Alonso, E. Soriano, J. Montaner, J. Masjuán, D.J. Hadjipavlou-  
635 Litina, J. Marco-Contelles, A. Alcázar, Cholesteronitrones for Stroke, *J. Med. Chem.* 58 (2015)  
636 6704–6709. doi:10.1021/acs.jmedchem.5b00755.
- 637 [24] F. Choteau, G. Durand, I. Ranchon-Cole, C. Cercy, B. Pucci, Cholesterol-based  $\alpha$ -phenyl-N-tert-  
638 butyl nitronone derivatives as antioxidants against light-induced retinal degeneration., *Bioorg.*  
639 *Med. Chem. Lett.* 20 (2010) 7405–9. doi:10.1016/j.bmcl.2010.10.037.
- 640 [25] H.Y. Zhang, D.P. Yang, G.Y. Tang, Multipotent antioxidants: from screening to design, *Drug*  
641 *Discov. Today.* 11 (2006) 749–754. doi:10.1016/j.drudis.2006.06.007.
- 642 [26] M. Koufaki, T. Calogeropoulou, A. Detsi, A. Roditis, A.P. Kourounakis, P. Papazafiri, K. Tsiakitzis,  
643 C. Gaitanaki, I. Beis, P.N. Kourounakis, Novel potent inhibitors of lipid peroxidation with  
644 protective effects against reperfusion arrhythmias, *J. Med. Chem.* 44 (2001) 4300–4303.  
645 doi:10.1021/jm010962w.
- 646 [27] E. Vavříková, V. Křen, L. Jezova-Kalachova, M. Biler, B. Chantemargue, M. Pyszková, S. Riva, M.  
647 Kuzma, K. Valentová, J. Ulrichová, J. Vrba, P. Trouillas, J. Vacek, Novel flavonolignan hybrid  
648 antioxidants: From enzymatic preparation to molecular rationalization, *Eur. J. Med. Chem.* 127

- 649 (2017) 263–274. doi:10.1016/j.ejmech.2016.12.051.
- 650 [28] J.J. Harnett, M. Auguet, I. Viossat, C. Dolo, D. Bigg, P.E. Chabrier, Novel lipoic acid analogues that  
651 inhibit nitric oxide synthase, *Bioorg. Med. Chem. Lett.* 12 (2002) 1439–1442. doi:Pii S0960-  
652 894x(02)00216-0\rDoi 10.1016/S0960-894x(02)00216-0.
- 653 [29] S. Ortial, G. Durand, B. Poeggeler, A. Polidori, M.A. Pappolla, J. Böker, R. Hardeland, B. Pucci,  
654 Fluorinated amphiphilic amino acid derivatives as antioxidant carriers: A new class of protective  
655 agents, *J. Med. Chem.* 49 (2006) 2812–2820. doi:10.1021/jm060027e.
- 656 [30] M. Rosselin, G. Meyer, P. Guillet, T. Cheviet, G. Walther, A. Meister, D. Hadjipavlou-Litina, G.  
657 Durand, Divalent Amino-Acid-Based Amphiphilic Antioxidants: Synthesis, Self-Assembling  
658 Properties, and Biological Evaluation, *Bioconjug. Chem.* 27 (2016) 772–781.  
659 doi:10.1021/acs.bioconjchem.6b00002.
- 660 [31] C. Der Mardirossian, M.P. Krafft, T. Gulik-Krzywicki, M. Le Maire, F. Lederer,  
661 Perfluoroalkylphosphocholines are poor protein-solubilizing surfactants, as tested with  
662 neutrophil plasma membranes, *Biochimie.* 80 (1998) 531–541. doi:10.1016/S0300-  
663 9084(00)80018-8.
- 664 [32] S.-W. Huang, E.N. Frankel, Antioxidant Activity of Tea Catechins in Different Lipid Systems, *J.*  
665 *Agric. Food Chem.* 45 (1997) 3033–3038. doi:10.1021/jf9609744.
- 666 [33] V. Kristinová, R. Mozuraityte, I. Storrø, T. Rustad, Antioxidant activity of phenolic acids in lipid  
667 oxidation catalyzed by different prooxidants, *J. Agric. Food Chem.* 57 (2009) 10377–10385.  
668 doi:10.1021/jf901072t.
- 669 [34] E. Niki, Free radical initiators as source of water- or lipid-soluble peroxy radicals., *Methods*  
670 *Enzymol.* 186 (1990) 100–8. doi:10.1016/0076-6879(90)86095-D.
- 671 [35] J. Werber, Y.J. Wang, M. Milligan, X. Li, J.A. Ji, Analysis of 2,2'-Azobis (2-amidinopropane)  
672 dihydrochloride degradation and hydrolysis in aqueous solutions, *J. Pharm. Sci.* 100 (2011)  
673 3307–3315. doi:10.1002/jps.22578.

- 674 [36] R.O. Recknagel, E.A. Glende, [40] Spectrophotometric Detection of Lipid Conjugated Dienes,  
675 Methods Enzymol. (1984). doi:10.1016/S0076-6879(84)05043-6.
- 676 [37] E. Schnitzer, I. Pinchuk, D. Lichtenberg, Peroxidation of liposomal lipids, Eur. Biophys. J. 36  
677 (2007) 499–515. doi:10.1007/s00249-007-0146-2.
- 678 [38] J.F.D. Liljeblad, V. Bulone, E. Tyrode, M.W. Rutland, C.M. Johnson, Phospholipid monolayers  
679 probed by vibrational sum frequency spectroscopy: Instability of unsaturated phospholipids,  
680 Biophys. J. 98 (2010) L50–L52. doi:10.1016/j.bpj.2010.02.009.
- 681 [39] E. Tyrode, P. Niga, M. Johnson, M.W. Rutland, Molecular structure upon compression and  
682 stability toward oxidation of langmuir films of unsaturated fatty acids: A vibrational sum  
683 frequency spectroscopy study, Langmuir. 26 (2010) 14024–14031. doi:10.1021/la102189z.
- 684 [40] P. Calvez, E. Demers, E. Boisselier, C. Salesse, Analysis of the contribution of saturated and  
685 polyunsaturated phospholipid monolayers to the binding of proteins, Langmuir. 27 (2011) 1373–  
686 1379. doi:10.1021/la104097n.
- 687 [41] É. Boisselier, É. Demers, L. Cantin, C. Salesse, How to gather useful and valuable information  
688 from protein binding measurements using Langmuir lipid monolayers, Adv. Colloid Interface Sci.  
689 243 (2017) 60–76. doi:10.1016/j.cis.2017.03.004.
- 690 [42] P. Suttiprasit, V. Krisdhasima, J. McGuire, The surface activity of  $\alpha$ -lactalbumin,  $\beta$ -lactoglobulin,  
691 and bovine serum albumin, J. Colloid Interface Sci. 154 (1992) 316–326. doi:10.1016/0021-  
692 9797(92)90146-D.
- 693 [43] R. Maget-Dana, M. Ptak, Behavior of insect defensin A at the air/water interface, Colloids  
694 Surfaces B Biointerfaces. 7 (1996) 135–143. doi:10.1016/0927-7765(96)01292-1.
- 695 [44] J.C. Stewart, Colorimetric determination of phospholipids with ammonium ferrothiocyanate.,  
696 Anal. Biochem. 104 (1980) 10–4. doi:10.1016/0003-2697(80)90269-9.
- 697 [45] E.L. Wu, X. Cheng, S. Jo, H. Rui, K.C. Song, E.M. Dávila-Contreras, Y. Qi, J. Lee, V. Monje-Galvan,  
698 R.M. Venable, J.B. Klauda, W. Im, CHARMM-GUI membrane builder toward realistic biological



- 699 membrane simulations, *J. Comput. Chem.* 35 (2014) 1997–2004. doi:10.1002/jcc.23702.
- 700 [46] Å.A. Skjevik, B.D. Madej, R.C. Walker, K. Teigen, LIPID11: A Modular Framework for Lipid  
701 Simulations Using Amber, *J. Phys. Chem. B.* 116 (2012) 11124–11136. doi:10.1021/jp3059992.
- 702 [47] J. Wang, R.M. Wolf, J.W. Caldwell, P.A. Kollman, D.A. Case, Development and testing of a general  
703 amber force field, *J. Comput. Chem.* 25 (2004) 1157–1174. doi:10.1002/jcc.20035.
- 704 [48] J. Wang, T. Hou, Application of molecular dynamics simulations in molecular property  
705 prediction. 1. Density and heat of vaporization, *J. Chem. Theory Comput.* 7 (2011) 2151–2165.  
706 doi:10.1021/ct200142z.
- 707 [49] D.L. Mobley, C.I. Bayly, M.D. Cooper, M.R. Shirts, K.A. Dill, Small molecule hydration free  
708 energies in explicit solvent: An extensive test of fixed-charge atomistic simulations, *J. Chem.*  
709 *Theory Comput.* 5 (2009) 350–358. doi:10.1021/ct800409d.
- 710 [50] K.N. Kirschner, A.B. Yongye, S.M. Tschampel, J. González-Outeiriño, C.R. Daniels, B.L. Foley, R.J.  
711 Woods, GLYCAM06: A generalizable biomolecular force field. carbohydrates, *J. Comput. Chem.*  
712 29 (2008) 622–655. doi:10.1002/jcc.20820.
- 713 [51] J. Wang, W. Wang, P.A. Kollman, D.A. Case, Automatic atom type and bond type perception in  
714 molecular mechanical calculations, *J. Mol. Graph. Model.* 25 (2006) 247–260.  
715 doi:10.1016/j.jmglm.2005.12.005.
- 716 [52] Y. Duan, C. Wu, S. Chowdhury, M.C. Lee, G. Xiong, W. Zhang, R. Yang, P. Cieplak, R. Luo, T. Lee, J.  
717 Caldwell, J. Wang, P. Kollman, A point-charge force field for molecular mechanics simulations of  
718 proteins based on condensed-phase quantum mechanical calculations, *J. Comput. Chem.* 24  
719 (2003) 1999–2012. doi:10.1002/jcc.10349.
- 720 [53] M.J. Frish, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V.  
721 Barone, G.A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. Marenich, J. Bloino, G. Janesko, R.  
722 Gomperts, B. Mennucci, H.P. Hratchian, V. Ortiz, A.F. Izmaylov, J.L. Sonnenberg, D. Williams-  
723 Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe,

724 V.G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J.  
725 Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssel, J.A.  
726 Montgomery, J.E. Peralta, F. Ogliaro, M. Bearpark, J.J. Heyd, E. Brothers, K.N. Kudin, V.N.  
727 Staroverov, T. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. Rendell, J.C. Burant, S.S.  
728 Iyengar, J. Tomasi, M. Cossi, J.M. Millam, M. Klene, C. Adamo, R. Cammi, J.W. Ochterski, R.L.  
729 Martin, K. Morokuma, O. Farkas, J.B. Foresman, D.J. Fox, Gaussian, Inc., Wallingford CT, 2016,  
730 n.d.

731 [54] F.-Y. Dupradeau, A. Pigache, T. Zaffran, C. Savineau, R. Lelong, N. Grivel, D. Lelong, W. Rosanski,  
732 P. Cieplak, The R.E.D. Tools: Advances in RESP and ESP charge derivation and force field library  
733 building, *Phys. Chem. Chem. Phys.* 12 (2010) 7821–7839. doi:10.1039/c0cp00111b.

734 [55] W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, M.L. Klein, Comparison of simple  
735 potential functions for simulating liquid water, *J. Chem. Phys.* 79 (1983) 926–935.  
736 doi:10.1063/1.445869.

737 [56] T. Darden, D. York, L. Pedersen, Particle mesh Ewald: An  $N \cdot \log(N)$  method for Ewald sums in  
738 large systems, *J. Chem. Phys.* 98 (1993) 10089–10092. doi:10.1063/1.464397.

739 [57] D.A. Case, D.S. Cerutti, T.E. Cheatham, T.A. Darden, R.E. Duke, T.J. Giese, H. Gohlke, A.W. Goetz,  
740 D. Greene, N. Homeyer, AMBER 2017; University of California: San Francisco, CA, USA, 2017,  
741 (n.d.).

742 [58] R. Salomon-Ferrer, D.A. Case, R.C. Walker, An overview of the Amber biomolecular simulation  
743 package, *Wiley Interdiscip. Rev. Comput. Mol. Sci.* 3 (2013) 198–210. doi:10.1002/wcms.1121.

744 [59] J.-P. Ryckaert, G. Ciccotti, H.J.C. Berendsen, Numerical integration of the cartesian equations of  
745 motion of a system with constraints: molecular dynamics of n-alkanes, *J. Comput. Phys.* 23  
746 (1977) 327–341. doi:10.1016/0021-9991(77)90098-5.

747 [60] R.J. Loncharich, B.R. Brooks, R.W. Pastor, Langevin dynamics of peptides: The frictional  
748 dependence of isomerization rates of N-acetylalanyl-N'-methylamide, *Biopolymers.* 32 (1992)

- 749 523–535. doi:10.1002/bip.360320508.
- 750 [61] H.J.C. Berendsen, J.P.M. Postma, W.F. Van Gunsteren, A. Dinola, J.R. Haak, Molecular dynamics  
751 with coupling to an external bath, *J. Chem. Phys.* 81 (1984) 3684–3690. doi:10.1063/1.448118.
- 752 [62] D.R. Roe, T.E. Cheatham, PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular  
753 Dynamics Trajectory Data, *J. Chem. Theory Comput.* 9 (2013) 3084–3095.  
754 doi:10.1021/ct400341p.
- 755 [63] G. Ottaviani, S. Wendelspiess, R. Alvarez-Sánchez, Importance of critical micellar concentration  
756 for the prediction of solubility enhancement in biorelevant media, *Mol. Pharm.* 12 (2015) 1171–  
757 1179. doi:10.1021/mp5006992.
- 758 [64] D. Marsh, Lateral pressure in membranes, *Biochim. Biophys. Acta - Rev. Biomembr.* 1286 (1996)  
759 183–223. doi:10.1016/S0304-4157(96)00009-3.
- 760 [65] M.P. Krafft, M. Goldmann, Monolayers made from fluorinated amphiphiles, *Curr. Opin. Colloid  
761 Interface Sci.* (2003). doi:10.1016/S1359-0294(03)00046-3.
- 762 [66] H. Nakahara, O. Shibata, Langmuir Monolayer Miscibility of Perfluorocarboxylic Acids with  
763 Biomembrane Constituents at the Air-Water Interface, *J. Oleo Sci.* (2012).  
764 doi:10.5650/jos.61.197.
- 765 [67] N. Funasaki, S. Hada, Coexistence of two kinds of mixed micelles, *J. Phys. Chem.* 84 (1980) 736–  
766 744. doi:10.1021/j100444a010.
- 767 [68] V. Peyre, S. Patil, G. Durand, B. Pucci, Mixtures of hydrogenated and fluorinated lactobionamide  
768 surfactants with cationic surfactants: Study of hydrogenated and fluorinated chains miscibility  
769 through potentiometric techniques, *Langmuir.* 23 (2007) 11465–11474. doi:10.1021/la701579e.
- 770 [69] S. Dong, G. Xu, H. Hoffmann, Aggregation Behavior of Fluorocarbon and Hydrocarbon Cationic  
771 Surfactant Mixtures: A Study of  $^1\text{H}$  NMR and  $^{19}\text{F}$  NMR, *J. Phys. Chem. B.* 112 (2008) 9371–  
772 9378. doi:10.1021/jp801216e.
- 773 [70] P. Barthélémy, V. Tomao, J. Selb, Y. Chaudier, B. Pucci, Fluorocarbon-hydrocarbon nonionic

- 774 surfactants mixtures: A study of their miscibility, *Langmuir*. 18 (2002) 2557–2563.  
775 doi:10.1021/la011600u.
- 776 [71] E. Frotscher, J. Höring, G. Durand, C. Vargas, S. Keller, Model-Free Analysis of Critical Micellar  
777 Concentrations for Detecting Demixing in Surfactant Mixtures, *Anal. Chem.* 89 (2017) 3245–  
778 3249. doi:10.1021/acs.analchem.7b00339.
- 779 [72] J.M.C. Gutteridge, B. Halliwell, Antioxidants: Molecules, medicines, and myths, *Biochem.*  
780 *Biophys. Res. Commun.* 393 (2010) 561–564. doi:10.1016/j.bbrc.2010.02.071.
- 781 [73] A. Kyrychenko, M. V. Rodnin, M. Vargas-Urbe, S.K. Sharma, G. Durand, B. Pucci, J.L. Popot, A.S.  
782 Ladokhin, Folding of diphtheria toxin T-domain in the presence of amphipols and fluorinated  
783 surfactants: Toward thermodynamic measurements of membrane protein folding, *Biochim.*  
784 *Biophys. Acta - Biomembr.* 1818 (2012) 1006–1012. doi:10.1016/j.bbamem.2011.09.012.
- 785 [74] C. Vargas, R.C. Arenas, E. Frotscher, S. Keller, Nanoparticle self-assembly in mixtures of  
786 phospholipids with styrene/maleic acid copolymers or fluorinated surfactants, *Nanoscale*. 7  
787 (2015) 20685–20696. doi:10.1039/c5nr06353a.
- 788 [75] E. Frotscher, B. Danielczak, C. Vargas, A. Meister, G. Durand, S. Keller, A Fluorinated Detergent  
789 for Membrane-Protein Applications, *Angew. Chemie Int. Ed.* 54 (2015) 5069–5073.  
790 doi:10.1002/anie.201412359.
- 791 [76] L. Socrier, M. Rosselin, F. Choteau, G. Durand, S. Morandat, Cholesterol-nitrone conjugates as  
792 protective agents against lipid oxidation: A model membrane study., *Biochim. Biophys. Acta.*  
793 1859 (2017) 2495–2504. doi:10.1016/j.bbamem.2017.09.026.
- 794 [77] D. Marquardt, J.A. Williams, N. Kučerka, J. Atkinson, S.R. Wassall, J. Katsaras, T.A. Harroun,  
795 Tocopherol activity correlates with its location in a membrane: A new perspective on the  
796 antioxidant vitamin e, *J. Am. Chem. Soc.* 135 (2013) 7523–7533. doi:10.1021/ja312665r.
- 797 [78] J. Garrec, A. Monari, X. Assfeld, L.M. Mir, M. Tarek, Lipid peroxidation in membranes: The  
798 peroxy radical does not “float,” *J. Phys. Chem. Lett.* 5 (2014) 1653–1658.

799 doi:10.1021/jz500502q.

- 800 [79] P. Košinová, K. Berka, M. Wykes, M. Otyepka, P. Trouillas, Positioning of Antioxidant Quercetin  
801 and Its Metabolites in Lipid Bilayer Membranes: Implication for Their Lipid-Peroxidation  
802 Inhibition, *J. Phys. Chem. B.* 116 (2012) 1309–1318. doi:10.1021/jp208731g.
- 803 [80] S. Azouzi, H. Santuz, S. Morandat, C. Pereira, F. Côté, O. Hermine, K. El Kirat, Y. Colin, C. Le Van  
804 Kim, C. Etchebest, P. Amireault, Antioxidant and Membrane Binding Properties of Serotonin  
805 Protect Lipids from Oxidation, *Biophys. J.* 112 (2017) 1863–1873. doi:10.1016/j.bpj.2017.03.037.
- 806 [81] T.C. Chou, P. Talalay, Quantitative analysis of dose-effect relationships: the combined effects of  
807 multiple drugs or enzyme inhibitors, *Adv. Enzyme Regul.* 22 (1984) 27–55. doi:10.1016/0065-  
808 2571(84)90007-4.
- 809 [82] M.C. Berenbaum, Criteria for analyzing interactions between biologically active agents, *Adv.*  
810 *Cancer Res.* 35 (1981) 269–335. doi:10.1016/S0065-230X(08)60912-4.
- 811 [83] C. Hennequin, N. Giocanti, V. Favaudon, Interaction of ionizing radiation with paclitaxel (taxol)  
812 and docetaxel (taxotere) in HeLa and SQ20B cells, *Cancer Res.* 56 (1996) 1842–1850.
- 813 [84] P. Palozza, N.I. Krinsky, Beta-Carotene and alpha-tocopherol are synergistic antioxidants, *Arch.*  
814 *Biochem. Biophys.* 297 (1992) 184–187. doi:10.1016/0003-9861(92)90658-J.
- 815 [85] H. Bai, R. Liu, H.L. Chen, W. Zhang, X. Wang, X. Di Zhang, W.L. Li, C.X. Hai, Enhanced antioxidant  
816 effect of caffeic acid phenethyl ester and Trolox in combination against radiation induced-  
817 oxidative stress, *Chem. Biol. Interact.* 207 (2014) 7–15. doi:10.1016/j.cbi.2013.10.022.
- 818 [86] G.T. Balogh, K. Vukics, Á. Könczöl, Á. Kis-Varga, A. Gere, J. Fischer, Nitron derivatives of trolox  
819 as neuroprotective agents, *Bioorg. Med. Chem. Lett.* 15 (2005) 3012–3015.  
820 doi:10.1016/j.bmcl.2005.04.043.
- 821 [87] G. Neunert, P. Górnaś, K. Dwiecki, A. Siger, K. Polewski, Synergistic and antagonistic effects  
822 between alpha-tocopherol and phenolic acids in liposome system: spectroscopic study, *Eur.*  
823 *Food Res. Technol.* 241 (2015) 749–757. doi:10.1007/s00217-015-2500-4.

- 824 [88] E.M. Becker, L.R. Nissen, L.H. Skibsted, Antioxidant evaluation protocols: Food quality or health  
825 effects, *Eur. Food Res. Technol.* 219 (2004) 561–571. doi:10.1007/s00217-004-1012-4.
- 826 [89] A. Kamal-Eldin, L.-Å. Appelqvist, The chemistry and antioxidant properties of tocopherols and  
827 tocotrienols, *Lipids*. 31 (1996) 671–701. doi:10.1007/BF02522884.
- 828 [90] G. Durand, A. Polidori, J.P. Salles, M. Prost, P. Durand, B. Pucci, Synthesis and antioxidant  
829 efficiency of a new amphiphilic spin-trap derived from PBN and lipoic acid, *Bioorganic Med.*  
830 *Chem. Lett.* 13 (2003) 2673–2676. doi:10.1016/S0960-894X(03)00545-6.
- 831 [91] L.R.C. Barclay, M.R. Vinqvist, Do spin traps also act as classical chain-breaking antioxidants? A  
832 quantitative kinetic study of phenyl tert-butyl nitron (PBN) in solution and in liposomes, *Free*  
833 *Radic. Biol. Med.* 28 (2000) 1079–1090. doi:10.1016/S0891-5849(00)00197-0.
- 834 [92] F. Franzoni, R. Colognato, F. Galetta, I. Laurenza, M. Barsotti, R. Di Stefano, R. Bocchetti, F.  
835 Regoli, A. Carpi, A. Balbarini, L. Migliore, G. Santoro, An in vitro study on the free radical  
836 scavenging capacity of ergothioneine: comparison with reduced glutathione, uric acid and  
837 trolox, *Biomed. Pharmacother.* 60 (2006) 453–457. doi:10.1016/j.biopha.2006.07.015.
- 838
- 839

840 **Figure's captions**

841 Fig. 1. Chemical structures and log*P* values of the studied molecules.

842

843 Fig. 2. Effect of the parent compounds and the fluorinated derivatives on the AAPH-induced oxidation  
844 of DLiPC SUVs. Kinetics of oxidation in presence of FATxPBN (A). IC<sub>50</sub> (μM) of Trolox (B), PBN (C), FATx  
845 (D), FAPBN (E) and FATxPBN (F). Results are presented as the mean ± standard deviation of at least  
846 three independent experiments.

847

848 Fig. 3. Lag time necessary to reach 10 and 20 % of oxidation. Results are presented as the mean ±  
849 standard deviation of at least three independent experiments.

850

851 Fig. 4. Surface activity (Gibbs monolayers) of the fluorinated antioxidants at the air/water interface.  
852 FATxPBN (A), FATx (B) and FAPBN (C). Data were fitted with a Langmuir equation with GraphPadPrism  
853 software.

854

855 Fig. 5. Interactions of fluorinated antioxidants with DLiPC monolayers. FATxPBN (A), FATx (B), FAPBN  
856 (C).

857

858 Fig. 6. Kinetics of penetration of the fluorinated antioxidants in DLiPC monolayers at 30 mN/m, which is  
859 the lateral pressure of biological membranes [64]. Evolution of the monolayer pressure after the  
860 injection of FAPBN, FATx and FATxPBN in DLiPC monolayers at 30 mN/m (A). Determination of the rate  
861 coefficient (*k*) after injection of the fluorinated antioxidants in the subphase of DLiPC monolayers (B).

862

863 Fig. 7. Representative snapshots of the preferred location of FATx (A), FAPBN (B) and FATxPBN (C). Fig.  
864 6D depicts the minor conformation of FAPBN, in which the PBN moiety is lined up along the fluorinated  
865 chain. The 1LB (β-D-Galactose), GA4 (gluconic acid), DAH (2,6-diaminohexanoic acid) and DFA  
866 (3,3,4,4,5,5,6,6,7,7,8,8,8-dodecafluorooctan-1-amine) moieties are depicted in red, blue, brown and  
867 yellow, respectively. Trolox and PBN are depicted in grey and pink, respectively. The cholines are  
868 depicted in cyan, the phosphates are depicted in magenta, 1<sup>st</sup> and 2<sup>nd</sup> unsaturations are depicted in  
869 green and dark-green, respectively.

870 **Table's captions**

871 Table 1. Binding parameters and rate of penetration ( $k$ ) of the fluorinated antioxidants in DLiPC  
872 monolayers.

873

874 Table 2. Positions given as distances from the middle of the bilayer (in Å) of key moieties of DLiPC (*i.e.*,  
875 choline, phosphates, saturations) and the different derivatives Trolox, Anionic Trolox, PBN, FATx,  
876 FAPBN, minor conformer of FAPBN (FAPBN\*) and FATxPBN (*i.e.*, Trolox moiety, Trolox OH-phenolic,  
877 PBN, PBN amine moiety, 1LB =  $\beta$ -D-Galactose, GA4 = gluconic acid; DAH = 2,6-diaminohexanoic acid,  
878 DFA = 3,3,4,4,5,5,6,6,7,7,8,8,8-dodecafluorooctan-1-amine), as well as center-of-mass (COM) of the  
879 three fluorinated antioxidants FATx, FAPBN and FATxPBN. The positions were averaged over the  
880 second half of the MD simulations.

881

882 Table 3. Combination index (CI) of FATx and FAPBN. CI<1: supra-additive, CI=1: additive, CI>1: infra-  
883 additive. Values with different superscripts differ significantly ( $p < 0.05$ ).

884






Fig. 1. Chemical structures and  $\log P$  values of the studied molecules.




Fig. 2. Effect of the parent compounds and the fluorinated derivatives on the AAPH-induced oxidation of DLPC liposomes. Kinetics of oxidation in presence of FATxPBN (A). IC<sub>50</sub> (μM) of Trolox (B), PBN (C), FATx (D), FAPBN (E) and FATxPBN (F). Results are presented as the mean ± standard deviation of at least three independent experiments.




Fig. 3. Lag time necessary to reach 10 and 20 % of oxidation. Results are presented as the mean  $\pm$  standard deviation of at least three independent experiments.




Fig. 4. Surface activity (Gibbs monolayers) of the fluorinated antioxidants at the air/water interface. FATxPBN (A), FATx (B) and FAPBN (C). Each experimental point was performed one time, as described in [40]. Data were fitted with a Langmuir equation with GraphPadPrism software.




Fig. 5. Interactions of fluorinated antioxidants with DLPC monolayers. FATxPBN (A), FATx (B), FAPBN (C). Upper right boxes: Kinetics of insertion of antioxidants at different surface pressures. Each experimental point was performed one time, as described in [40].




Fig. 6 Kinetics of penetration of the fluorinated antioxidants in DLiPC monolayers at 30 mN/m, which is the lateral pressure of biological membranes [64]. Evolution of the monolayer pressure after the injection of FAPBN, FATx and FATxPBN in DLiPC monolayers at 30 mN/m (A). Determination of the rate coefficient ( $k$ ) after injection of the fluorinated antioxidants in the subphase of DLiPC monolayers (B).




Fig. 7. Representative snapshots of the preferred location of FATx (A), FAPBN (B) and FATxPBN (C). Fig. 6D depicts the minor conformation of FAPBN, in which the PBN moiety is lined up along the fluorinated chain. The 1LB ( $\beta$ -D-Galactose), GA4 (gluconic acid), DAH (2,6-diaminohexanoic acid) and DFA (3,3,4,4,5,5,6,6,7,7,8,8,8-dodecafluorooctan-1-amine) moieties are depicted in red, blue, brown and yellow, respectively. Trolox and PBN are depicted in grey and pink, respectively. The cholines are depicted in cyan, the phosphates are depicted in magenta, 1<sup>st</sup> and 2<sup>nd</sup> unsaturations are depicted in green and dark-green, respectively.

Table 1. Binding parameters and rate of penetration ( $k$ ) of the fluorinated antioxidants in DLiPC monolayers.


	FATxPBN	FATx	FAPBN
MIP (mN/m)	52.2 ± 2.3	48.6 ± 5.3	37.6 ± 5.3
$\Delta\Pi_{30}$ (mN/m)	10.0 ± 0.4	9.0 ± 1.5	2.1 ± 1.1
Synergy factor	0.55 ± 0.02	0.52 ± 0.06	0.71 ± 0.05
$k$ (s <sup>-1</sup> )	1.11*10 <sup>-2</sup>	1.17*10 <sup>-2</sup>	0.52*10 <sup>-2</sup>





**Table 3. Combination index (CI) of FATx and FAPBN. CI<1: supra-additive, CI=1: additive, CI>1: infra-additive. Values with different superscripts differ significantly ( $p < 0.05$ ).**

<b>Concentration (<math>\mu\text{M}</math>)</b>	<b>Combination index</b>	<b>Effect</b>
0,4	0,46 <sup>a</sup>	Supra-additive
0,6	0,69 <sup>a</sup>	Supra-additive
0,8	0,92 <sup>a</sup>	Supra-additive
1,6	1,83 <sup>b</sup>	Infra-additive
3,2	3,66 <sup>b</sup>	Infra-additive
6,4	7,33 <sup>b</sup>	Infra-additive
12,8	14,66 <sup>b</sup>	Infra-additive
25,6	29,31 <sup>b</sup>	Infra-additive
38,4	43,97 <sup>b</sup>	Infra-additive



Lipid vesicles

